For poorly water-soluble BCS Class II drugs (e.g., fenofibrate, itraconazole), which advanced formulation technology converts the crystalline drug into a high-energy amorphous state dispersed within a hydrophilic polymer carrier (e.g., HPMC-AS, PVP-VA) to maintain supersaturation in the GI tract?
- AHot-Melt Extrusion (HME) producing an Amorphous Solid Dispersion (ASD)
- BDirect compression with hydrophobic ethylcellulose matrices
- CAqueous pan coating with shellac resins
- DHigh-shear wet granulation using heavy mineral oil